The University of Oxford has unveiled exciting new data in the treatment of the novel coronavirus, with a randomised clinical trial proving the efficacy of the corticosteroid dexamethasone in reducing mortality rates in COVID-19-infected patients requiring respiratory intervention
In the study, 2,104 participants were randomised to receive 6mg dexamethasone either intravenously or orally for ten days, while 4,321 were randomised to receive only usual care.
Image caption: Image Credit: Mathew Horwood, Getty Images
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
